Table 3.
Electrocardiographic and echocardiographic data of adolescents with chest pain and suspected myocarditis related to COVID-19 vaccination.
| Variables | Value |
|---|---|
| ECG tested, n (%) | 40 (100) |
| Abnormal | 21 (52.5) |
| Normal | 19 (47.5) |
| ECG findings, overlaps allowed | |
| ST and/or T wave changes | 7 (17.5) |
| Ventricular tachycardia | 1 (2.5) |
| Low-voltage QRS | 0 |
| Premature ventricular contractions | 2 (5.0) |
| Premature atrial contractions | 1 (2.5) |
| Sinus tachycardia | 4 (10.0) |
| Sinus bradycardia | 5 (12.5) |
| ECHO tested, n (%) | 40 (100) |
| Left ventricular function, n (%) | 40 (100) |
| EF (%), median (range; IQR) | 65 (range 40–88; IQR 59–71) |
| Normal EF, > 55%, n (%) | 34 (85) |
| Mildly impaired EF, 41–55%, n (%) | 6 (15) |
| E/A (n = 39) | 1.83 (range 1.07–3.87; IQR 1.45–2.12) |
| Abnormal E/A, n (%) | 0 |
| E/E’ (n = 40) | 7.59 (range 4.22–12.07; IQR 6.87–8.42) |
| Abnormal E/E’, n (%) | 0 |
| Right ventricular function, n (%) | 22 (57.5) |
| TAPSE (absolute value, mm), median (range; IQR) | 23 (range 17–33; IQR 21–26.5) |
| Abnormal TAPSE, n (%) | 0 |
| Mitral valve insufficiency, n (%) | 8 (20) |
| Pericardial effusion, n (%) | 3 (7.5) |
ECG, electrocardiogram; ECHO, echocardiogram; EF, ejection fraction; IQR, interquartile range; TAPSE, tricuspid annular plane systolic excursion.